We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aerie (AERI) to Report Q2 Earnings: What's in the Offing?
Read MoreHide Full Article
Aerie Pharmaceuticals, Inc. is expected to report second-quarter 2018 results on Aug 7.
Last quarter, the company reported a narrower-than-expected loss. Aerie’s performance over the last four quarters has been disappointing. The company incurred a narrower-than-expected loss in two of the trailing four quarters, while reporting wider-than-expected loss in the remaining two, with an average negative surprise of 3.30%.
Aerie Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Aerie’s shares have returned 13.4% in the year so far against the industry’s 0.4% decline.
Factors at Play
In December 2017, Aerie's lead drug, Rhopressa, was approved by the FDA for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Glaucoma is one of the largest segments in the global ophthalmic market. According to the National Eye Institute, it is estimated that more than 2.7 million individuals in the United States suffer from glaucoma. This number is expected to reach 4.3 million by 2030.
Hence, the approval is likely to boost Aerie’s top line significantly. Aerie is securing formulary contracts to enable commercial coverage in 2018 and Medicare Part D coverage in 2019. The company expects preferred formulary coverage for the majority of commercial plans by the end of 2018, and preferred formulary coverage for the majority of Medicare Part D plans commencing in 2019. Aerie expects Rhopressa’s revenues to be in the range of $20-$30 million in 2018. We expect management to throw more light on the drug’s launch, during the second-quarter call.
Meanwhile, Aerie’s New Drug Application (NDA) for its second product candidate, Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed-dose combination of Rhopressa and Pfizer’s (PFE - Free Report) Xalatan, was submitted to the FDA in May 2018. Last week, the company received the “Day 74” notification from the FDA, earlier than scheduled. The agency has completed its initial 60-day review of the NDA and determined that the application is sufficiently complete to permit a substantive review. The PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA’s review of the Roclatan NDA is set for Mar 14, 2019. The “Day 74” notification indicates that the FDA has not identified any potential review issues and might not need an advisory committee review. Investors will also be focussed on Aerie’s update on the same.
On the other hand, operating expenses are expected to increase in relation to Rhopressa’s launch. Total cash burn for 2018 is projected in the range of $200-$210 million.
Earnings Whispers
Our proven model does not show that Aerie is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen, which is not the case here:
Earnings ESP: The Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -0.33%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Aerie has a Zacks Rank #1, which is favorable. However, we need to have a positive Earnings ESP as well to be confident of an earnings beat.
Note, we caution against Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement, especially when the company is seeing a negative estimate revision.
Stocks to Consider
Here are a few health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Jazz Pharmaceuticals Plc (JAZZ - Free Report) has an Earnings ESP of +1.43% and currently carries a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 7.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Aerie (AERI) to Report Q2 Earnings: What's in the Offing?
Aerie Pharmaceuticals, Inc. is expected to report second-quarter 2018 results on Aug 7.
Last quarter, the company reported a narrower-than-expected loss. Aerie’s performance over the last four quarters has been disappointing. The company incurred a narrower-than-expected loss in two of the trailing four quarters, while reporting wider-than-expected loss in the remaining two, with an average negative surprise of 3.30%.
Aerie Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Aerie Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Aerie Pharmaceuticals, Inc. Quote
Aerie’s shares have returned 13.4% in the year so far against the industry’s 0.4% decline.
Factors at Play
In December 2017, Aerie's lead drug, Rhopressa, was approved by the FDA for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Glaucoma is one of the largest segments in the global ophthalmic market. According to the National Eye Institute, it is estimated that more than 2.7 million individuals in the United States suffer from glaucoma. This number is expected to reach 4.3 million by 2030.
Hence, the approval is likely to boost Aerie’s top line significantly. Aerie is securing formulary contracts to enable commercial coverage in 2018 and Medicare Part D coverage in 2019. The company expects preferred formulary coverage for the majority of commercial plans by the end of 2018, and preferred formulary coverage for the majority of Medicare Part D plans commencing in 2019. Aerie expects Rhopressa’s revenues to be in the range of $20-$30 million in 2018. We expect management to throw more light on the drug’s launch, during the second-quarter call.
Meanwhile, Aerie’s New Drug Application (NDA) for its second product candidate, Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed-dose combination of Rhopressa and Pfizer’s (PFE - Free Report) Xalatan, was submitted to the FDA in May 2018. Last week, the company received the “Day 74” notification from the FDA, earlier than scheduled. The agency has completed its initial 60-day review of the NDA and determined that the application is sufficiently complete to permit a substantive review. The PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA’s review of the Roclatan NDA is set for Mar 14, 2019. The “Day 74” notification indicates that the FDA has not identified any potential review issues and might not need an advisory committee review. Investors will also be focussed on Aerie’s update on the same.
On the other hand, operating expenses are expected to increase in relation to Rhopressa’s launch. Total cash burn for 2018 is projected in the range of $200-$210 million.
Earnings Whispers
Our proven model does not show that Aerie is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen, which is not the case here:
Earnings ESP: The Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -0.33%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Aerie has a Zacks Rank #1, which is favorable. However, we need to have a positive Earnings ESP as well to be confident of an earnings beat.
Note, we caution against Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement, especially when the company is seeing a negative estimate revision.
Stocks to Consider
Here are a few health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) has an Earnings ESP of +42.86% and currently carries a Zacks Rank #2. The company is scheduled to release second-quarter results on Aug 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Jazz Pharmaceuticals Plc (JAZZ - Free Report) has an Earnings ESP of +1.43% and currently carries a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 7.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>